company background image
MCET

MultiCell Technologies OTCPK:MCET Stock Report

Last Price

US$0.000001

Market Cap

US$5.0k

7D

0%

1Y

0%

Updated

25 Mar, 2024

Data

Company Financials

MultiCell Technologies, Inc.

OTCPK:MCET Stock Report

Market Cap: US$5.0k

MCET Stock Overview

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications.

MCET fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

MultiCell Technologies, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MultiCell Technologies
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.0005
52 Week LowUS$0.000001
Beta0
1 Month Change0%
3 Month Change0%
1 Year Change0%
3 Year Change-99.92%
5 Year Change-99.00%
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

MCETUS BiotechsUS Market
7D0%-0.06%2.1%
1Y0%9.8%30.4%

Return vs Industry: MCET underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: MCET underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is MCET's price volatile compared to industry and market?
MCET volatility
MCET Average Weekly Movementn/a
Biotechs Industry Average Movement11.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: MCET has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MCET's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1962n/aJerry Newmin

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications.

MultiCell Technologies, Inc. Fundamentals Summary

How do MultiCell Technologies's earnings and revenue compare to its market cap?
MCET fundamental statistics
Market capUS$5.00k
Earnings (TTM)-US$253.60k
Revenue (TTM)US$805.24k

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCET income statement (TTM)
RevenueUS$805.24k
Cost of RevenueUS$216.92k
Gross ProfitUS$588.31k
Other ExpensesUS$841.92k
Earnings-US$253.60k

Last Reported Earnings

Aug 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did MCET perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.